Trials / Conditions / Gallbladder Carcinoma

Gallbladder Carcinoma

23 registered clinical trials studyying Gallbladder Carcinoma — 4 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Trifluridine/Tipiracil + Oxaliplatin in Participants With Advanced or Metastatic Biliary Tract Cancer NCT07146646	Case Comprehensive Cancer Center	Phase 2
Recruiting	Target-specific immunoPET Imaging of Digestive System Carcinoma NCT06715839	RenJi Hospital	N/A
Unknown	Therapeutic Assistance and Decision-making Algorithms in Hepatobiliary Tumor Boards NCT05681949	Charite University, Berlin, Germany	N/A
Active Not Recruiting	A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid NCT05712356	Lisata Therapeutics, Inc.	Phase 2
Recruiting	Pressurized Intraperitoneal Aerosolized Nab-Paclitaxel in Combination With Gemcitabine and Cisplatin for the T NCT05285358	City of Hope Medical Center	Phase 1
Completed	Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Usin NCT06789224	Lindis Bloodcare GmbH	N/A
Terminated	A Study of Felmetatug Vedotin/SGN-B7H4V in Advanced Solid Tumors NCT05194072	Seagen, a wholly owned subsidiary of Pfizer	Phase 1
Completed	A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumor NCT04853017	Elicio Therapeutics	Phase 1
Terminated	Study of Irinotecan Liposome Injection in Patients With Advanced Biliary Tract Cancer NCT05009953	CSPC Ouyi Pharmaceutical Co., Ltd.	Phase 2
Completed	A Dual Channel Supraglottic Airway Device (LMA Gastro) for Oxygenation in Patients Undergoing ERCP NCT04740164	M.D. Anderson Cancer Center	N/A
Active Not Recruiting	Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER NCT04430738	Seagen, a wholly owned subsidiary of Pfizer	Phase 2
Recruiting	Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA NCT04183712	Shanghai Jiao Tong University School of Medicine	Phase 2
Unknown	Apapitatin Combined With SOX for Palliative Adjuvant Chemotherapy in Patients With Advanced Gallbladder Carcin NCT03702491	Eastern Hepatobiliary Surgery Hospital	Phase 2
Completed	Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be NCT03201458	National Cancer Institute (NCI)	Phase 2
Unknown	A Study of Circulating Exosome Proteomics In Gallbladder Carcinoma Patients NCT03581435	liu yingbin	—
Active Not Recruiting	Comprehensive Genomic Profiling Combined With Real Life Data of "The German-Registry of Incidental Gallbladder NCT05222854	Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest	—
Active Not Recruiting	Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013	National Cancer Institute (NCI)	Phase 2
Completed	Unilateral Stenting Versus Bilateral Stenting for Malignant Hilar Biliary Obstruction NCT02649712	Xuzhou Central Hospital	N/A
Withdrawn	A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer NCT02105350	University Health Network, Toronto	Phase 1
Completed	Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer NCT02333188	University of Chicago	Phase 1
Active Not Recruiting	A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone NCT02151084	University Health Network, Toronto	Phase 2
Terminated	Clinical Trial to Investigate the Efficacy of Treatment With Gemcitabine/Pazopanib in Patients With Biliary Tr NCT01855724	Hellenic Cooperative Oncology Group	Phase 2
Terminated	Permission to Collect Blood Over Time for Research NCT00767234	Stanford University	—